Name:
Introduction to AI in Precision Oncology with EIC Doug Flora
Description:
Introduction to AI in Precision Oncology with EIC Doug Flora
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/f8c3b6cb-311c-4753-a9de-e909ae13753f/videoscrubberimages/Scrubber_1.jpg?sv=2019-02-02&sr=c&sig=ncJjAF9xguAyd%2F08ALGr3NiEEA5OGmObFazf1JcfNeY%3D&st=2024-05-09T18%3A42%3A03Z&se=2024-05-09T22%3A47%3A03Z&sp=r
Duration:
T00H04M08S
Embed URL:
https://stream.cadmore.media/player/f8c3b6cb-311c-4753-a9de-e909ae13753f
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/f8c3b6cb-311c-4753-a9de-e909ae13753f/EIC_Doug_Flora_Revised.mp4?sv=2019-02-02&sr=c&sig=qVx89LvsPssVTTCkizN1LGruHTTDnT36vVyYpTc9daw%3D&st=2024-05-09T18%3A42%3A03Z&se=2024-05-09T20%3A47%3A03Z&sp=r
Upload Date:
2023-11-11T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
[MUSIC PLAYING]
KEVIN DAVIES: I'm very excited to be joined by Doug Flora, M.D. the executive medical director in Oncology Sciences at Saint Elizabeth Health Care, serving patients in Kentucky and Ohio primarily, and more importantly, the inspirational founding editor in chief of AI in Precision Oncology, a very exciting new journal launching in early 2024. Many congratulations, Doug. Great to see you.
DOUGLAS FLORA: Thanks, Kevin. Glad to be here.
KEVIN DAVIES: Two questions for today's proceedings. One, why is AI so important for medicine in general and oncology in particular? And when did you see the light?
DOUGLAS FLORA: Well, I'm about to go downstairs and see about 25 cancer patients that are desperate for help. I've got a team of about 50 cancer doctors in the building that are beleaguered and overworked and time-bankrupt. And so I'm looking for a way to get these tools in the hands of the doctors and the nurses that are caring for patients. We know that AI and technology can help them. We know that it can give them time to be back in the room with patients instead of typing on a computer.
DOUGLAS FLORA: And I wanted to find a way to get a peer-reviewed powerful tool together to consolidate this information and share it with the patients' caretakers as fast and as legitimately in a peer-reviewed fashion as possible.
KEVIN DAVIES: When did you first get switched on to the possibilities of artificial intelligence?
DOUGLAS FLORA: I think we've all gotten used to it, democratizing our lives with Siri and Cortana and our digital assistants. In my own life, I started using these tools in medicine about four years ago. And I think we've seen what the advent of generative AI, things like ChatBot, GPT, and other things. We're starting to see the ways that these things can make our lives more efficient. And that's something cancer doctors desperately need.
DOUGLAS FLORA: There just are not enough of us for the number of cancer patients in our charge.
KEVIN DAVIES: So we've only just announced you as the chief editor of AI in Precision Oncology. You're busy assembling the editorial board, getting ready for the formal press release, and, of course, planning that all-important preview issue and the big launch next year. What everyone in the room wants to know is, why should libraries subscribe to AI in Precision Oncology in 2024.
DOUGLAS FLORA: Right. Well, that's important. And I care about this question. We've assembled so far about a dozen of the international leaders in artificial intelligence in oncology, who are the Vanguard of how these things work and how we can get them actually used in the clinics. I would say that librarians, they're seeing in their worlds exactly what we're seeing in our worlds.
DOUGLAS FLORA: And there's no reliable peer-reviewed place to get information you can trust. Right now, it's industry leading all these conversations. I'd like to make sure that it's evidence-based science that's leading these conversations.
KEVIN DAVIES: The papers you hope to be publishing in the journal, I mean, this is life-saving research. Would you just end by saying a little bit about that?
DOUGLAS FLORA: Yes, I'm confident that this journal will save lives. I'm confident that getting these tools in the hands of oncologists will help us diagnose people earlier with AI reading films or microscopic slides. I'm very confident it will make us develop drugs faster and cleaner and better with fewer toxicities for the patients I'm about to see downstairs. And most importantly, I'm confident it will make your oncologists who treat your cancer and your family better because they're going to have more information available and more time to spend with the patient, which is ultimately making care more human.
KEVIN DAVIES: Fantastic, Doug. Let's leave it there for now. We're going to be talking much more to you in the weeks and months ahead. But best of luck in getting the journal off the ground. We can't wait to work more closely with you. All the best. [MUSIC PLAYING]